Latest Cancer News
SATURDAY, June 5 (HealthDay News) -- Researchers report they prolonged survival for some patients with advanced non-small cell lung cancer, for whom the median survival is currently only about six months.
One study discovered that an experimental drug called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5% of lung cancer patients, or roughly 40,000 people worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited elderly patients, who represent the majority of those with lung cancer worldwide. Roughly 100,000 patients with lung cancer in the United States are over the age of 70.
"This is our toughest cancer in many ways," said Dr. Mark Kris, moderator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220,000 Americans each year, and over a million people worldwide. Sadly, it is our nation's -- and our world's -- leading cancer."
The first study, a phase 1 trial, found that 87% of 82 patients with advanced non-small cell lung cancer with a specific mutation of the ALK gene, which makes that gene fuse with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc.
"The patients were treated for an average of six months, and more than 90% saw their tumors shrink in size and 72% of participants remained progression-free six months after treatment," said study author Dr. Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10% of patients would be expected to respond to treatment.
The fusion gene was first discovered to play a role in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported financial ties to Pfizer.
The second study, a phase 3 trial, involved 451 patients with advanced non-small cell lung cancer aged 70 to 89. The study had first expected to enroll 520 patients, but it was halted early when good survival results were seen in the group taking the combination therapy.
Currently, elderly patients are typically given just one chemotherapy drug, with younger patients more likely to get two or more.
In this trial, participants were randomly selected to receive either one chemotherapy agent -- gemcitabine (Gemzar) or vinorelbine (Navelbine) -- or to receive both carboplatin and paclitaxel (Taxol).
For the single-agent group, median survival at one year was 6.2 months and 27% patients were still alive, "which is consistent with previous research," said study author Dr. Elisabeth Quoix, a professor of medicine at University Hospital in Strasbourg, France.
"In the double-therapy group, the median survival increased by four months [to 10.3 months], which is quite unusual in thoracic oncology," Quoix said. "Forty-five percent of patients survived one year, which is also quite unusual."
"The four-month improvement is a huge one," added Kris, who is chief of thoracic oncology at Memorial Sloan-Kettering Cancer Center in New York City. "Other large clinical trials ... have generally felt to be practice-changing with a two-month change in median survival. This trial supports the idea that patients over 70 should be treated just as anyone else."
Quoix and other study authors reported ties with different pharmaceutical companies, including Eli Lilly Co. and Roche Inc.
Finally, a phase 3 study out of the University of Texas M.D. Anderson Cancer Center in Houston found patients receiving the targeted drug vandetanib combined with chemotherapy had a 21% decline in disease progression compared to those receiving chemotherapy alone. Median progression-free survival in the combination arm was 17.3 weeks vs. 14 weeks in the control group.
This study was simultaneously presented Saturday at the ASCO meeting and published in The Lancet Oncology.
Kris also reported ties with several pharmaceutical firms.
Copyright © 2010 HealthDay. All rights reserved.